Singapore markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
350.15-3.80 (-1.07%)
At close: 04:00PM EST
350.70 +0.55 (+0.16%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close353.95
Bid349.41 x 900
Ask350.80 x 800
Day's range348.46 - 354.35
52-week range282.21 - 387.42
Avg. volume1,210,545
Market cap90.228B
Beta (5Y monthly)0.42
PE ratio (TTM)26.31
EPS (TTM)13.31
Earnings date05 Feb 2024 - 09 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est400.00
  • Motley Fool

    Forget the "Magnificent Seven": Buy This Stock Instead

    With the Nasdaq Composite up by 36% this year, those equities known as the "Magnificent Seven" have done quite a bit of the work. The company in question is biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX).

  • Motley Fool

    2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years

    These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.

  • Yahoo Finance Video

    FDA approves gene-editing therapy for sickle cell disease

    The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements. Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient's stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient - relieving painful symptoms. Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC's. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.